

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR
HBM9378/SKB378 (ANTI-TSLP) FOR COPD TO THE NATIONAL MEDICAL
PRODUCTS ADMINISTRATION OF CHINA

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group has submitted an Investigational New Drug (“**IND**”) application to the Centre for Drug Evaluation of the National Medical Products Administration of China (the “**CDE**”) for HBM9378 (or SKB378, as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6690.HK) and the Company’s partner in the development of HBM9378), a fully human antibody targeting thymic stromal lymphopoietin (“**TSLP**”), for the treatment of chronic obstructive pulmonary disease (“**COPD**”).

The Company will work closely with the regulatory authorities to complete the application and targets to bring this precision therapy to COPD patients who are in need of novel treatment options.

About HBM9378/SKB378

HBM9378/SKB378 is a co-development project conducted by the Company and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6690.HK) who together equally share the global rights in respect of HBM9378/SKB378. HBM9378/SKB378 is a fully human monoclonal antibody against TSLP generated from two heavy chains and two light chains (H2L2) platform. It inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor, its long half-life optimization and outstanding biophysical properties support the favorable dosing advantage. Currently, the Company had completed the phase I trial in China under IND for the treatment of moderate-to-severe asthma.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM9378/SKB378. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 8 November 2024

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive directors; Ms. Weiwei Chen as non-executive directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Dr. Albert R. Collinson as independent non-executive directors.